Leverage a global network of Phase I clinical pharmacology units to build diversity in patient populations and access a range of geographic regions for early clinical development (ECD) programs.
It is challenging to navigate biosimilars regulation and the payer landscape, provide real world evidence to physicians, and compete for the right sites and patients. IQVIA can help you overcome these obstacles and make better decisions throughout your study's lifecycle using a customized approach backed by expertise in more than 15 therapeutic areas.
It starts when you leverage the power of the IQVIA Connected Intelligence™. This is how we use unparalleled data, transformative technology, advanced analytics, and scientific expertise to help achieve study goals and bring biosimilar drugs to market faster.
Customizable scope of solutions to meet your study needs
The trajectory of biosimilars has changed – and according to current projections, will continue on an upward path. With continued increases in biologics spending expected, the biosimilars market presents an opportunity for savings on medicines.
Leverage a global network of Phase I clinical pharmacology units to build diversity in patient populations and access a range of geographic regions for early clinical development (ECD) programs.
Navigate complex regulatory requirements with expert insights and bring transparency, efficiency and predictability to your regulatory affairs strategy.
Strengthen your portfolio by making more informed decisions and fewer assumptions, and prepare for the impact of new research discoveries and events.
IQVIA is using vast quantities of data in powerful new ways. See how we can help you tap into information from past trials, patient reported outcomes and other sources to accelerate your research.